{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,3]],"date-time":"2026-05-03T13:13:15Z","timestamp":1777813995930,"version":"3.51.4"},"reference-count":16,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100005612","name":"Shionogi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005612","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014935","name":"BioCryst","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014935","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["229733"],"award-info":[{"award-number":["229733"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.antiviral.2019.104561","type":"journal-article","created":{"date-parts":[[2019,7,16]],"date-time":"2019-07-16T01:59:57Z","timestamp":1563242397000},"page":"104561","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["The Val430Ile neuraminidase (NA) substitution, identified in influenza B virus isolates, impacts the catalytic 116Arg residue causing reduced susceptibility to NA inhibitors"],"prefix":"10.1016","volume":"170","author":[{"given":"Yacine","family":"Abed","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cl\u00e9ment","family":"Fage","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liva","family":"Checkmahomed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriel","family":"Begin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie","family":"Carbonneau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Lague","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guy","family":"Boivin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2019.104561_bib1","doi-asserted-by":"crossref","first-page":"838","DOI":"10.3201\/eid2504.181554","article-title":"Reduced susceptibility to neuraminidase inhibitors in influenza B isolate, Canada","volume":"25","author":"Abed","year":"2019","journal-title":"Emerg. Infect. Dis."},{"issue":"5","key":"10.1016\/j.antiviral.2019.104561_bib2","article-title":"Dominant influenza A(H3N2) and B\/Yamagata virus circulation in EU\/EEA, 2016\/17 and 2017\/18 seasons, respectively","volume":"23","author":"Adlhoch","year":"2018","journal-title":"Eur. Surveill. Mar."},{"key":"10.1016\/j.antiviral.2019.104561_bib3","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0166-3542(01)00219-4","article-title":"Susceptibility of recent Canadian influenza A and B virus isolates to different neuraminidase inhibitors","volume":"54","author":"Boivin","year":"2002","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2019.104561_bib4","doi-asserted-by":"crossref","first-page":"2972","DOI":"10.1128\/jvi.67.6.2972-2980.1993","article-title":"Sequence and structure alignment of paramyxovirus hemagglutinin-neuraminidase with influenza virus neuraminidase","volume":"67","author":"Colman","year":"1993","journal-title":"J. Virol."},{"issue":"1","key":"10.1016\/j.antiviral.2019.104561_bib5","doi-asserted-by":"crossref","DOI":"10.3390\/v11010006","article-title":"In vitro properties and virulence of contemporary recombinant influenza B viruses harboring mutations of cross-resistance to neuraminidase inhibitors","volume":"11","author":"Fage","year":"2018","journal-title":"Viruses"},{"key":"10.1016\/j.antiviral.2019.104561_bib6","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1001\/jama.297.13.1435","article-title":"Emergence of influenza B viruses with reduced sensitivity to neuraminidase inhibitors","volume":"297","author":"Hatakeyama","year":"2007","journal-title":"Jama"},{"key":"10.1016\/j.antiviral.2019.104561_bib7","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1086\/505868","article-title":"A comparison of the effectiveness of oseltamivir for the treatment of influenza A and influenza B: a Japanese multicenter study of the 2003-2004 and 2004-2005 influenza seasons","volume":"43","author":"Kawai","year":"2006","journal-title":"Clin. Infect. Dis."},{"issue":"Suppl. 1","key":"10.1016\/j.antiviral.2019.104561_bib8","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/irv.12047","article-title":"Influenza neuraminidase inhibitors: antiviral action and mechanisms of resistance","volume":"7","author":"McKimm-Breschkin","year":"2013","journal-title":"Influenza Other Respir. Viruses"},{"key":"10.1016\/j.antiviral.2019.104561_bib9","doi-asserted-by":"crossref","first-page":"e43","DOI":"10.2105\/AJPH.2012.301137","article-title":"The burden of influenza B: a structured literature review","volume":"103","author":"Paul Glezen","year":"2013","journal-title":"Am. J. Public Health"},{"key":"10.1016\/j.antiviral.2019.104561_bib10","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/0042-6822(90)90186-U","article-title":"Cocirculation of two distinct evolutionary lineages of influenza type B virus since 1983","volume":"175","author":"Rota","year":"1990","journal-title":"Virology"},{"key":"10.1016\/j.antiviral.2019.104561_bib11","doi-asserted-by":"crossref","first-page":"5220","DOI":"10.1128\/AAC.03313-14","article-title":"Characterization of drug-resistant influenza virus A(H1N1) and A(H3N2) variants selected in vitro with laninamivir","volume":"58","author":"Samson","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2019.104561_bib12","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.antiviral.2013.03.014","article-title":"Influenza virus resistance to neuraminidase inhibitors","volume":"98","author":"Samson","year":"2013","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2019.104561_bib13","doi-asserted-by":"crossref","first-page":"3870","DOI":"10.1128\/JCM.02464-09","article-title":"Evaluation of three influenza A and B real-time reverse transcription-PCR assays and a new 2009 H1N1 assay for detection of influenza viruses","volume":"48","author":"Selvaraju","year":"2010","journal-title":"J. Clin. Microbiol."},{"issue":"5","key":"10.1016\/j.antiviral.2019.104561_bib14","article-title":"Early season co-circulation of influenza A(H3N2) and B(Yamagata): interim estimates of 2017\/18 vaccine effectiveness, Canada, January 2018","volume":"23","author":"Skowronski","year":"2018","journal-title":"Eur. Surveill. Feb"},{"key":"10.1016\/j.antiviral.2019.104561_bib15","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.antiviral.2016.11.007","article-title":"The I427T neuraminidase (NA) substitution, located outside the NA active site of an influenza A(H1N1)pdm09 variant with reduced susceptibility to NA inhibitors, alters NA properties and impairs viral fitness","volume":"137","author":"Tu","year":"2017","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2019.104561_bib16","first-page":"497","article-title":"Global monitoring of antiviral resistance in currently circulating human influenza viruses, November 2011","volume":"86","author":"WHO","year":"2011","journal-title":"Wkly. Epidemiol. Rec."}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354219302219?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354219302219?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T21:11:22Z","timestamp":1777497082000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354219302219"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":16,"alternative-id":["S0166354219302219"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2019.104561","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Val430Ile neuraminidase (NA) substitution, identified in influenza B virus isolates, impacts the catalytic 116Arg residue causing reduced susceptibility to NA inhibitors","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2019.104561","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"104561"}}